Chief People Officer
Elias Berglund has served as our Chief People Officer since May 2023, and brings more than 15 years of human resources experience at global and growing companies across different industries. Prior to joining Olink, from August 2020 until April 2023, Mr. Berglund worked at Universum Communications AB as Global Chief HR Officer. Prior to that he served seven years in various positions, mainly as Chief HR Officer at Tre AB; with additional experience from Klarna and SF Bio AB. Mr. Berglund studied behavioral science in Stockholm.
Chief Executive Officer
Jon Heimer has served as the chairman of Olink Proteomics AB since 2014 and Chief Executive Officer of Olink Proteomics AB since January 2016 and has served as a member of our Board of Directors since December 2020. Prior to joining us, from April 2011 until December 2015, Mr. Heimer was a partner at Nexttobe AB, a family office/investment company focused on the Swedish biotechnology industry. Mr. Heimer has served as chairman of the board of directors of Q-linea AB, and for multiple privately-held biotechnology companies, including Bioimics AB and Lumina Adhesives AB. Mr. Heimer is a serial entrepreneur, was one of the key persons in successful Q-Med starting off in the 1990’s and has spent a large part of his professional career working from the United States in various investments and growth companies within the biotech space.
Chief Financial Officer
Oskar Hjelm has served as our Chief Financial Officer since March 2020. Prior to joining us, from September 2017 until February 2020, Mr. Hjelm worked at Alvarez & Marsal Sweden AB within their Transaction Advisory Group providing support to European and Nordic private equity funds. From August 2016 until August 2017, Mr. Hjelm was a director at KPMG AB. From January 2016 until August 2016, Mr. Hjelm was an investment controller at Nordic Capital. From July 2008 until December 2015, Mr. Hjelm held various roles at KPMG AB and KPMG LLP (United Kingdom). Mr. Hjelm received his Master of Science in business and economics from Linköping University.
Rickard El Tarzi
Chief Strategy Officer
Rickard El Tarzi has served as our Chief Strategy Officer since February 2020 and served as a member of our Board of Directors from March 2019 to February 2020. Prior to joining us, from January 2017 until February 2020, Mr. El Tarzi served as an investment director on the investment team of Summa Equity AB. From April 2012 until April 2016, Mr. El Tarzi worked at McKinsey & Company advising investor and corporate clients across Europe and the United States on strategy and mergers and acquisitions. Mr. El Tarzi received his Bachelor of Science in logistics and transport management and his Master of Science in management from University of Gothenburg School of Business, Economics, and Law.
Chief Scientific Officer
Ida Grundberg, PhD has served as our Chief Scientific Officer since September 2019. Prior to joining us, from September 2011 until September 2019, Dr. Grundberg served in various roles at our subsidiary, Olink Proteomics AB, including Senior Scientist, Project Manager, Business Development Manager, Head of Business Development for North America, and Vice President of Sales and Marketing for North America. Dr. Grundberg received her Bachelor of Science from Umeå University, her Master of Science in molecular biology from Umeå University, and her PhD in molecular medicine from Uppsala University.
Chief Operating Officer
Anna Marsell joined Olink as Chief Operating Officer in November 2022. She brings more than 15 years of international experience from the pharma and medtech industry with various roles in R&D, project management, sales and marketing, as well as company governance and general management. Her most recent role is General Manager for the Nordic region of Galderma, delivering sustainable organic growth and increased market share. During her 10 years at Galderma she has held various senior leadership roles in global strategic marketing, product development, commercial operations, Uppsala Site management, as well as in strategic corporate governance when based in Galderma HQ in Lausanne, Switzerland. Prior to joining Galderma, Anna spent 7 years in various R&D and product marketing roles within medtech, focused on cardiovascular technology at Radi Medical Systems and St. Jude Medical in the U.S. and Sweden.
Carl joined Olink in August 2020, and as President, he is responsible for Commercial, Operations, Human Resources, Product and Corporate Strategy. He previously served as Olink Chief Commercial Officer, and as our Senior Vice President of Sales. Prior to joining us, from January 2015 until February 2020, Mr. Raimond served in various executive commercial leadership roles at PerkinElmer, Inc. including Vice President and General Manager of Americas Sales and Service and Global Vice President and General Manager of Sales and Service for the Discovery and Analytical Solutions Division. From June 2010 until January 2015, Mr. Raimond served as the Vice President and General Manager of the Americas Life Science Sales & Field Operations of Agilent Technologies, Inc. Mr. Raimond received his Bachelor of Arts in zoology from State University of New York College at Oswego, and his Master of Science in biology from State University of New York College at Brockport.
Linda Ramirez-Eaves, Esq. has served as our General Counsel since February 2019. Prior to joining us, Ms. Ramirez-Eaves served as Senior Counsel of SomaLogic, Inc. from September 2015 until December 2018. Ms. Ramirez-Eaves has served as the Secretary of the Board of Directors since January 2021. Ms. Ramirez-Eaves received her Bachelor of Science in Journalism and Mass Communications from the University of Colorado at Boulder, and her Juris Doctorate from the University of Colorado at Boulder School of Law. Ms. Ramirez- Eaves has been a Certified Information Privacy Professional/Europe since 2018. Ms. Ramirez-Eaves currently serves as Vice-Chair of the Association of Corporate Counsel, Women in the House Network, as well as serving on the board of the Latinas First Foundation.
Chief Commercial Officer
Bruno Rossi joined Olink as Chief Commercial Officer in March 2023. He brings more than 25 years of global experience in the life sciences industry, including the laboratory, pharmaceutical, and diagnostic market segments; and with senior strategic roles in product management, sales and marketing, and R&D. Before joining Olink, Bruno held multiple leadership positions at Leica Microsystems (a Danaher company) most recently serving as Vice President Global Business Transformation. Previous to Leica Microsystems, Bruno spent 22 years at Millipore (now part of Merck KGaA) holding various senior positions in sales, marketing, and product management. Bruno holds a Master's degree in Organic Chemistry from École Nationale Supérieure de Chimie de Clermont-Ferrand (ENSCCF).